NEW YORK - Waldencast plc (NASDAQ: WALD), a global beauty and wellness platform, announced the appointment of three new members to its board of directors on Monday. The new appointments, effective since September 26, 2024, include Hind Sebti, co-founder and Chief Growth Officer of Waldencast, Kelly Brookie, a retired Deloitte Audit Partner, and Roberto Thompson Motta, a co-founder of 3G Capital.
The board expansion brings diverse expertise, particularly in the beauty, financial, and consumer products sectors. Sebti's 20-year experience in managing beauty brands is expected to provide valuable consumer insights and assist portfolio brands in scaling. Brookie, with over 25 years in financial accounting and reporting, will join the Audit and Governance Committee, while Thompson, with his extensive investment firm background, will serve on the Finance Committee.
The company also announced its Annual General Meeting scheduled for October 28, 2024, where shareholders will vote on the renewal of Class I and Class II directors. The board now comprises 11 members, each with significant sector-specific expertise.
Waldencast expressed gratitude to outgoing board member Sarah Brown for her contributions, particularly as chair of the Nominating and Corporate Governance Committee and member of the Audit Committee.
The company, known for its multi-brand platform, aims to scale high-growth purpose-driven brands while maintaining their distinct identities. Waldencast's portfolio includes Obagi Medical, a skin care line, and Milk Makeup, a vegan and cruelty-free cosmetics brand.
Felipe Dutra, Chairman of the Board, stated, "We are pleased to announce that Hind, Kelly, and Roberto are joining our Board of Directors. Each brings distinct and diverse skill sets that we believe will be highly valuable to us as we execute our long-term vision."
The information in this article is based on a press release statement.
In other recent news, Waldencast Acquisition Corp. has been making significant strides in both the skincare and financial sectors. The company's skincare subsidiary, Obagi Medical, has introduced two new products to its ELASTIDERM® collection, the Lift Up & Sculpt Facial Moisturizer and the Advanced Filler Concentrate. These products, designed to enhance skin appearance and texture, have been clinically tested and are now available for purchase.
In addition to these product releases, Waldencast has also experienced substantial financial developments. The company's second-quarter sales surpassed expectations, leading investment firm DA Davidson to raise its stock target for Waldencast from $6.50 to $7.25. Despite an EBITDA miss due to an underestimation of the typical seasonal decline, Waldencast's Obagi and Milk brands have seen significant sales growth.
DA Davidson has revised its 2024 sales growth estimate for Waldencast to 24% year-over-year, up from the initially projected 15%, and has also increased its EBITDA estimates by 7%. The new price target is based on a 27-times multiple of the firm's revised 2025 EBITDA projection of $50 million. These are the recent developments for Waldencast.
InvestingPro Insights
As Waldencast plc (NASDAQ: WALD) announces its board expansion, investors might be interested in some key financial metrics and insights provided by InvestingPro.
Despite the company's recent leadership changes, InvestingPro data shows that Waldencast's market capitalization stands at $419.51 million. The company boasts impressive gross profit margins of 69.71% for the last twelve months as of Q2 2024, which aligns with one of the InvestingPro Tips highlighting "impressive gross profit margins." This strong margin could provide the new board members with a solid foundation to work from as they aim to scale the company's high-growth brands.
However, it's worth noting that Waldencast's revenue for the same period was $240.38 million, with a revenue growth of -12.74%. This decline in revenue might be one of the challenges the newly appointed directors will need to address.
Another InvestingPro Tip indicates that analysts anticipate sales growth in the current year. This positive outlook could be a result of the strategic board appointments and their potential to drive growth in Waldencast's portfolio brands like Obagi Medical and Milk Makeup.
For investors considering Waldencast's stock, it's important to note that the company's price-to-book ratio stands at 0.67, suggesting the stock might be undervalued relative to its book value. This could present an opportunity for value investors, especially considering the company's efforts to strengthen its leadership team.
These insights are just a snapshot of the information available on InvestingPro. The platform offers 10 additional tips for Waldencast, providing a more comprehensive analysis for investors interested in this beauty and wellness platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.